16 assets in Peripheral Primitive Neuroectodermal Tumor

Therapeutic assets addressing Peripheral Primitive Neuroectodermal Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Palbociclib Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	B (57)
PI3K/MTOR INHIBITOR LY3023414 Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	B (57)
Tazemetostat Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	B (57)
Vemurafenib Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	CCC (55)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Ensartinib Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Ivosidenib Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Olaparib Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Selpercatinib Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Ulixertinib Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Onivyde Peripheral Primitive Neuroectodermal Tumor	St. Jude Children's Research Hospital	P1/2	CCC (48)
Talazoparib Peripheral Primitive Neuroectodermal Tumor	St. Jude Children's Research Hospital	P1/2	CCC (48)
Edotreotide Peripheral Primitive Neuroectodermal Tumor	ITM Solucin GmbH	P1	CC (43)